Conexeu Sciences Announces $5 Million Private Placement Led by Existing Shareholders, Management and Directors

Financial Post ·
Canada

Financing involving participation from the CEO and Chief Commercial Officer, supports manufacturing scale-up, regulatory testing and preclinical work toward the Company’s planned FDA 510(k) submission in the first quarter of 2027 RENO, Nev., Oct. 15, 2026 (GLOBE NEWSWIRE) — Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage medical device and regenerative…

Read original article on Financial Post →

Related news